Key Points
- Giles Wilson, an insider at Dr. Martens, bought 219 shares on Feb. 11 at GBX 69 (total £151.11), after prior purchases of 192 shares on Jan. 13 (GBX 78) and 197 shares on Dec. 11 (GBX 76), signaling repeated insider buying.
- DOCS opened at GBX 68.62 and was trading up about 2.0%; its 50-day and 200-day moving averages are GBX 73.90 and GBX 82.17, respectively, with a market cap of £663.29m, P/E of 40.37 and a 52-week range of GBX 43.02–100.87.
- Analysts are split (two Buy, two Hold) with an average rating of "Moderate Buy" and an average price target reported as GBX 6,000.
Dr. Martens plc (LON:DOCS - Get Free Report) insider Giles Wilson bought 219 shares of the firm's stock in a transaction dated Wednesday, February 11th. The stock was purchased at an average price of GBX 69 per share, for a total transaction of £151.11.
Giles Wilson also recently made the following trade(s):
- On Tuesday, January 13th, Giles Wilson purchased 192 shares of Dr. Martens stock. The stock was purchased at an average cost of GBX 78 per share, for a total transaction of £149.76.
- On Thursday, December 11th, Giles Wilson acquired 197 shares of Dr. Martens stock. The stock was purchased at an average cost of GBX 76 per share, with a total value of £149.72.
Dr. Martens Trading Up 2.0%
Shares of DOCS stock opened at GBX 68.62 on Friday. The stock's fifty day moving average is GBX 73.90 and its two-hundred day moving average is GBX 82.17. The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85. The firm has a market capitalization of £663.29 million, a P/E ratio of 40.37, a PEG ratio of 6.40 and a beta of 0.11. Dr. Martens plc has a fifty-two week low of GBX 43.02 and a fifty-two week high of GBX 100.87.
Dr. Martens (LON:DOCS - Get Free Report) last released its earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share (EPS) for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. Research analysts expect that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research firms have weighed in on DOCS. Berenberg Bank reissued a "buy" rating on shares of Dr. Martens in a research note on Tuesday, January 27th. Royal Bank Of Canada reaffirmed a "sector perform" rating on shares of Dr. Martens in a report on Tuesday, February 3rd. Finally, Peel Hunt restated a "buy" rating on shares of Dr. Martens in a report on Thursday, November 20th. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of GBX 6,000.
Read Our Latest Research Report on DOCS
About Dr. Martens
(
Get Free Report)
Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
